Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Carboplatin 273 Paclitaxel 267 Gemcitabine 244 Bevacizumab 226 Cisplatin 218 pembrolizumab 214 Docetaxel 210 Pemetrexed 162 Capecitabine 148 Fluorouracil 129 Oxaliplatin 121 Cyclophosphamide 121 Nivolumab 112 Dexamethasone 100 Trastuzumab 89 Leucovorin 87 Cetuximab 85 Rituximab 83 Irinotecan 82 Injections 81 Erlotinib Hydrochloride 70 Prednisone 68 Doxorubicin 68 Temozolomide 67 atezolizumab 65 Bortezomib 65 Ipilimumab 64 Fulvestrant 59 Radiotherapy 54 Drug Therapy 51

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × azeliragon × Clear all

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡